---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-027791"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T10:35:58.388406+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics moves to block Liquidia's PH-ILD product with preliminary injunction and FDA suit

## Summary
- Filed preliminary injunction motion in Delaware on Feb 26, 2024, alleging Liquidia's PH-ILD product infringes U.S. Patent No. 11,826,327 (expires 2042).
- Separately sued FDA in D.C., arguing Liquidia must submit a new NDA for PH-ILD, which would trigger a 30-month stay.
- Liquidia's inhaled treprostinil is tentatively approved for PAH but not PH-ILD; United's Tyvaso is approved for both PAH and PH-ILD.
- If injunction or stay granted, Liquidia cannot market its product for PH-ILD while patent litigation proceeds.

## SEC filing metadata
- accession: 0001104659-24-027791
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465924027791/0001104659-24-027791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465924027791/tm247282d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-027791
- JSON: https://secwatch.observer/filing/0001104659-24-027791.json
- Plain text: https://secwatch.observer/filing/0001104659-24-027791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.